Men's Health (UK) - - Time -


The trial in­ves­ti­gat­ing “spon­ta­neously oc­cur­ring mys­ti­cal ex­pe­ri­ences” that sparked psychedelics’ come­back took place at Johns Hop­kins School of Medicine in Bal­ti­more. Vol­un­teers tripped out to clas­si­cal mu­sic on a sofa.


A team of sci­en­tists in Cal­i­for­nia led by Charles Grob found psilo­cy­bin im­proved the mood of ter­mi­nally ill pa­tients for up to six months, as well as re­duc­ing their anxiety. Pa­tients also re­ported feel­ing closer to their friends and fam­ily.


Nor­we­gian sci­en­tists trawled through 1960s LSD stud­ies. They found a sin­gle trip seemed to have “a sig­nif­i­cant ben­e­fi­cial ef­fect” on al­co­holics. They wrote: “It’s puz­zling why this treat­ment has been largely over­looked.”


Re­peated ke­tamine in­fu­sions were shown to have an an­tide­pres­sant ef­fect on those re­sis­tant to treat­ment in a study by the Mount Sinai School of Medicine in New York. The ef­fects lasted for 18 days at a time.


Many have called SSRI an­tide­pres­sants into ques­tion. Har­vard Med­i­cal School’s Irv­ing Kirsch sug­gested they are no more than place­bos. “The sero­tonin the­ory is as close as any in the his­tory of science to hav­ing been proved wrong,” he wrote.


Last year, Im­pe­rial Col­lege Lon­don con­ducted the first clin­i­cal trial into psilo­cy­bin as a vi­able treat­ment for de­pres­sion. Af­ter just two ses­sions, all 12 vol­un­teers showed markedly im­proved symp­toms.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.